# Kliniken Essen-Mitte

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/kliniken-essen-mitte/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 71 |
| Citations | 375,708 |
| City | Essen |
| Country | DE |
| Description | Kliniken Essen-Mitte is a research organisation in Essen, DE. OpenAlex records 4,836 works and 375,708 citations for it. 915 researchers list it as their most recent affiliation. |
| Homepage | http://www.kliniken-essen-mitte.de/ |
| OpenAlex ID | https://openalex.org/I4210146447 |
| Researchers | 915 |
| ROR ID | https://ror.org/03v958f45 |
| Type | healthcare |
| Works | 4,836 |

## University papers

Showing 12 of 17.

- [Pembrolizumab for Early Triple-Negative Breast Cancer](https://scholariq.org/papers/pembrolizumab-for-early-triple-negative-breast-cancer/)
- [A Phase 3 Trial of Bevacizumab in Ovarian Cancer](https://scholariq.org/papers/a-phase-3-trial-of-bevacizumab-in-ovarian-cancer/)
- [Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy](https://scholariq.org/papers/tumour-infiltrating-lymphocytes-and-prognosis-in-different-subtypes-of-breast/)
- [ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease](https://scholariq.org/papers/esmo-esgo-consensus-conference-recommendations-on-ovarian-cancer-pathology-and/)
- [Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial](https://scholariq.org/papers/neoadjuvant-carboplatin-in-patients-with-triple-negative-and-her2-positive-early/)
- [Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers](https://scholariq.org/papers/tumor-infiltrating-lymphocytes-and-response-to-neoadjuvant-chemotherapy-with-or/)
- [A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study](https://scholariq.org/papers/a-randomised-phase-ii-study-investigating-durvalumab-in-addition-to-an/)
- [A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms](https://scholariq.org/papers/a-randomized-trial-of-lymphadenectomy-in-patients-with-advanced-ovarian/)
- [Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study](https://scholariq.org/papers/neoadjuvant-treatment-with-trastuzumab-in-her2-positive-breast-cancer-results/)
- [Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR Trial](https://scholariq.org/papers/surgery-in-recurrent-ovarian-cancer-the-arbeitsgemeinschaft-gynaekologische/)
- [Treatment of recurrent ovarian cancer](https://scholariq.org/papers/treatment-of-recurrent-ovarian-cancer/)
- [Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer](https://scholariq.org/papers/prospective-validation-study-of-a-predictive-score-for-operability-of-recurrent/)

## University top topics

Showing 8 of 25.

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [Complementary and Alternative Medicine Studies](https://scholariq.org/topics/complementary-and-alternative-medicine-studies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.